LH · Labcorp Holdings Inc.

Healthcare NYQ United States labcorp.com ↗
Val Gro Qua Mom Sta Cap P/S1.76 P/E Fwd P/E15.72 PEG1.26 52W –  RSI Target$342.73 (+10.0%) Beta0.85 Div0.94%
Loading chart…
RSI ()
Pattern Overlays
Loading patterns…
Diagnostics & Research Burlington, United States 71,000 employees
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low 52W High
Position in Range
RSI (14)
0 · Oversold RSI 40 Overbought · 100
Signal Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
9Bullish
3Bearish
0Neutral

Key Signals 3

▲ Double Bottom Major reversal 2026-06-05 · $263.93
Two lows ~$251.19 — bullish reversal confirmed
Learn more →
▲ Double Bottom Major reversal 2026-06-29 · $275.0
Two lows ~$253.06 — bullish reversal confirmed
Learn more →
▲ Double Bottom Major reversal 2026-07-24 · $291.38
Two lows ~$257.58 — bullish reversal confirmed
Learn more →

Momentum Signals 9

▲ MACD Bullish Crossover 2026-05-20 · $256.71
▲ MACD Bullish Crossover 2026-06-25 · $266.34
▲ MACD Bullish Crossover 2026-07-23 · $291.02
▲ Bull Flag 2026-08-07 · $317.1

View overlays on the price chart via Overview tab → Pattern Overlays.

Next Earnings Oct 27, 2026
Beat Rate 100%
Consensus BUY
Analyst Upside +10.0%
EPS — History & Forecast
Estimate Beat Miss Forecast
Loading…
Revenue — History & Forecast
Revenue Forecast
Loading…
EPS Beat Rate
100% 8/8 quarters
Wall Street Consensus
BUY
12
4
1
BuyHoldSell
Price Target Range
$342.73 +10.0% upside
Low $293 High $385
Consensus Current price
Wall Street Analyst Ratings
Sort by
Firm Rating Change Action Date
Profitability
Gross Margin 28.88%Last 12 Months
Operating Margin 12.24%Last 12 Months
Return on Equity 11.73%Last 12 Months
Revenue Growth 5.80%Year over Year
Free Cash Flow 892.05MLast 12 Months
Free Cash Flow Yield Last 12 Months
Balance Sheet
Debt / Equity 79.12Most Recent Quarter
Current Ratio 1.80Most Recent Quarter
Cash 141.80MMost Recent Quarter
Total Debt 6.82BMost Recent Quarter
Net Debt Most Recent Quarter
How LH Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
QuarterRevenueRev YoYGross Profit Op. IncomeNet IncomeNet YoY Gross %Op %Net %
Full Key Statistics
Valuation
Market Cap25.27B
Enterprise Value31.96B
Trailing P/E25.39
Forward P/E15.72
PEG Ratio (5yr)1.26
Price/Sales (ttm)1.76
Price/Book (mrq)2.93
EV/Revenue2.23
EV/EBITDA13.78
Share Statistics
Avg Vol (3m)693.12K
Shares Outstanding81.10M
Float80.72M
% Held by Insiders0.35%
% Held by Institutions101.89%
Short Ratio3.45
Short % of Float2.60%
Profitability
Gross Margin28.88%
Operating Margin (ttm)12.24%
Profit Margin6.99%
Return on Assets (ttm)5.53%
Return on Equity (ttm)11.73%
Income Statement
Revenue (ttm)14.35B
Revenue Growth (yoy)5.80%
Gross Profit (ttm)4.14B
EBITDA2.32B
Net Income (ttm)1.00B
Diluted EPS (ttm)12.27
EPS Growth (yoy)28.20%
Balance Sheet
Total Cash (mrq)141.80M
Total Debt (mrq)6.82B
Debt / Equity (mrq)79.12
Current Ratio (mrq)1.80
Book Value / Share106.39
Operating CF (ttm)1.64B
Free Cash Flow (ttm)892.05M
Trading & Dividends
Beta (5Y)0.85
50-Day MA308.97
200-Day MA276.43
Fwd Dividend Yield0.94%
Payout Ratio23.82%
Income
Dividend Yield 0.94%Last 12 Months
Annual Rate 2.88Forward
Payout Ratio 23.82%Last 12 Months
Dividend History
Payout Ratio (Last 12 Months): 23.82%
Monthly Dividends
Ownership Breakdown
Institutional 101.89% Insider 0.35%
Short Interest 2.60% of float
Low
Institutional 13F Holdings

Famous investors who disclosed a position in LH in their latest SEC 13F filing.

Loading…
Insider Transactions
Date Insider Role Transaction Shares Price Value